289 related articles for article (PubMed ID: 25575032)
1. Current state of prognostication and risk stratification in myelodysplastic syndromes.
Zeidan AM; Gore SD; Padron E; Komrokji RS
Curr Opin Hematol; 2015 Mar; 22(2):146-54. PubMed ID: 25575032
[TBL] [Abstract][Full Text] [Related]
2. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?
Nazha A; Sekeres MA; Gore SD; Zeidan AM
Oncologist; 2015 Sep; 20(9):1069-76. PubMed ID: 26194858
[TBL] [Abstract][Full Text] [Related]
3. The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions.
Lee EJ; Podoltsev N; Gore SD; Zeidan AM
Blood Rev; 2016 Jan; 30(1):1-10. PubMed ID: 26119927
[TBL] [Abstract][Full Text] [Related]
4. New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice.
Tothova Z; Steensma DP; Ebert BL
Clin Cancer Res; 2013 Apr; 19(7):1637-43. PubMed ID: 23329810
[TBL] [Abstract][Full Text] [Related]
5. There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.
Zeidan AM; Komrokji RS
Curr Hematol Malig Rep; 2013 Dec; 8(4):351-60. PubMed ID: 23979829
[TBL] [Abstract][Full Text] [Related]
6. Personalized Risk Schemes and Machine Learning to Empower Genomic Prognostication Models in Myelodysplastic Syndromes.
Awada H; Gurnari C; Durmaz A; Awada H; Pagliuca S; Visconte V
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269943
[TBL] [Abstract][Full Text] [Related]
7. Prognostication in myelodysplastic syndromes (neoplasms): Molecular risk stratification finally coming of age.
Xie Z; Chen EC; Stahl M; Zeidan AM
Blood Rev; 2023 May; 59():101033. PubMed ID: 36357283
[TBL] [Abstract][Full Text] [Related]
8. Prognostic mutation constellations in acute myeloid leukaemia and myelodysplastic syndrome.
Iacobucci I; Mullighan CG
Curr Opin Hematol; 2021 Mar; 28(2):101-109. PubMed ID: 33427759
[TBL] [Abstract][Full Text] [Related]
9. Molecular Data and the IPSS-R: How Mutational Burden Can Affect Prognostication in MDS.
Nazha A; Bejar R
Curr Hematol Malig Rep; 2017 Oct; 12(5):461-467. PubMed ID: 28844082
[TBL] [Abstract][Full Text] [Related]
10. When to use which molecular prognostic scoring system in the management of patients with MDS?
Kewan T; Bewersdorf JP; Gurnari C; Xie Z; Stahl M; Zeidan AM
Best Pract Res Clin Haematol; 2023 Dec; 36(4):101517. PubMed ID: 38092484
[TBL] [Abstract][Full Text] [Related]
11. Prognostic scoring systems and risk stratification in myelodysplastic syndrome: focus on integration of molecular profile.
Ball S; Komrokji RS; Sallman DA
Leuk Lymphoma; 2022 Jun; 63(6):1281-1291. PubMed ID: 34933652
[TBL] [Abstract][Full Text] [Related]
12. Novel therapeutic strategies in myelodysplastic syndromes: do molecular genetics help?
Chung SS
Curr Opin Hematol; 2016 Mar; 23(2):79-87. PubMed ID: 26825694
[TBL] [Abstract][Full Text] [Related]
13. Genetic Testing in Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Nardi V; Hasserjian RP
Surg Pathol Clin; 2016 Mar; 9(1):143-63. PubMed ID: 26940274
[TBL] [Abstract][Full Text] [Related]
14. Implications of molecular genetic diversity in myelodysplastic syndromes.
Bejar R
Curr Opin Hematol; 2017 Mar; 24(2):73-78. PubMed ID: 27875374
[TBL] [Abstract][Full Text] [Related]
15. The evolving role of genomic testing in assessing prognosis of patients with myelodysplastic syndromes.
Steensma DP
Best Pract Res Clin Haematol; 2017 Dec; 30(4):295-300. PubMed ID: 29156198
[TBL] [Abstract][Full Text] [Related]
16. Recent Clinical and Molecular Advances for the Classification of Myelodysplastic Neoplasms.
DeZern AE; Greenberg PL
J Natl Compr Canc Netw; 2022 Dec; 20(12):1280-1283. PubMed ID: 36509078
[TBL] [Abstract][Full Text] [Related]
17. Prognostic models in myelodysplastic syndromes.
Bejar R
Hematology Am Soc Hematol Educ Program; 2013; 2013():504-10. PubMed ID: 24319225
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: A meta-analysis.
Tang Y; Miao M; Han S; Qi J; Wang H; Ruan C; Wu D; Han Y
Crit Rev Oncol Hematol; 2019 Jan; 133():74-83. PubMed ID: 30661660
[TBL] [Abstract][Full Text] [Related]
19. Therapy-related myelodysplastic syndromes, or are they?
Abou Zahr A; Kavi AM; Mukherjee S; Zeidan AM
Blood Rev; 2017 May; 31(3):119-128. PubMed ID: 27923516
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.
Thol F; Friesen I; Damm F; Yun H; Weissinger EM; Krauter J; Wagner K; Chaturvedi A; Sharma A; Wichmann M; Göhring G; Schumann C; Bug G; Ottmann O; Hofmann WK; Schlegelberger B; Heuser M; Ganser A
J Clin Oncol; 2011 Jun; 29(18):2499-506. PubMed ID: 21576631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
